Ian Flinn, MD, PhD, Sarah Cannon Research Institute
Advertisement
Articles by Ian Flinn, MD, PhD, Sarah Cannon Research Institute
Advertisement
Latest Updated Articles
R2 Regimen for R/R Follicular LymphomaPublished: March 15th 2021 | Updated:
Role of Rebiopsy in R/R Follicular LymphomaPublished: March 1st 2021 | Updated:
Treating R/R DLBCL With CAR-T: Current BarriersPublished: February 26th 2021 | Updated:
Tazemetostat for R/R Follicular LymphomaPublished: March 22nd 2021 | Updated:
CAR T-Cell Therapy for R/R DLBCLPublished: February 19th 2021 | Updated:
R/R DLBCL: Transplants in the Era of CAR-TPublished: March 12th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5